Senescent Immunity in Elders and Vaccine Responses (SILVER)
Phase 4
Completed
- Conditions
- Flu Vaccine
- Registration Number
- NCT04077424
- Lead Sponsor
- Vanderbilt University Medical Center
- Brief Summary
To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
- Age 65 years and over
- Independent Living (including Assisted Living)
Exclusion Criteria
- Unable to understand the consent or the study.
- Allergic to any vaccine components, excluding eggs.
- History of Guillain-Barre.
- Residing in a long -term care facility such as a nursing home.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Hemagglutinin Antigen Inhibition Assay Titers at Day 28 Day 28 Baseline 2 fold dilution series of serum, and measurement of titer which inhibits hemagglutination.
Titers were measured for each of 4 antigens in the vaccine (A/Brisbane/2018 (H1N1), A/Kansas/2017 (H3N2), B/Colorado/2017 (Vic), B/Phuket/2013 (Yam))Hemagglutinin Antigen Inhibition Assay Titers at Baseline Baseline Baseline 2 fold dilution series of serum, and measurement of titer which inhibits hemagglutination.
Titers were measured for each of 4 antigens in the vaccine (A/Brisbane/2018 (H1N1), A/Kansas/2017 (H3N2), B/Colorado/2017 (Vic), B/Phuket/2013 (Yam))
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Vanderbilt University Medical Center🇺🇸Nashville, Tennessee, United States